prikaz prve stranice dokumenta Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report
  Download
PDF 289.58 KB
Scientific paper - Case study
Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report
Medicina, 59 (2023), 9; 1517. https://doi.org/10.3390/medicina59091517
Kilić, Paula; Ikić, Lucija; Mayer, Miroslav; Artuković, Marinko; Maštrović Radončić, Ksenija; Ikić Matijašević, Marina

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Kilić, P., Ikić, L., Mayer, M., Artuković, M., Maštrović Radončić, K. & Ikić Matijašević, M. (2023). Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report. Medicina, 59. (9). doi: 10.3390/medicina59091517

Kilić, Paula, et al. "Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report." Medicina, vol. 59, no. 9, 2023. https://doi.org/10.3390/medicina59091517

Kilić, Paula, Lucija Ikić, Miroslav Mayer, Marinko Artuković, Ksenija Maštrović Radončić and Marina Ikić Matijašević. "Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report." Medicina 59, no. 9 (2023). https://doi.org/10.3390/medicina59091517

Kilić, P., et al. (2023) 'Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report', Medicina, 59(9). doi: 10.3390/medicina59091517

Kilić P, Ikić L, Mayer M, Artuković M, Maštrović Radončić K, Ikić Matijašević M. Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report. Medicina [Internet]. 2023 August 23 [cited 2024 November 29];59(9). doi: 10.3390/medicina59091517

P. Kilić, L. Ikić, M. Mayer, M. Artuković, K. Maštrović Radončić and M. Ikić Matijašević, "Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report", Medicina, vol. 59, no. 9, August 2023. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:091889. [Accessed: 29 November 2024]

Metadata
Title (english)Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report
AuthorPaula Kilić
AuthorLucija Ikić
AuthorMiroslav Mayer
AuthorMarinko Artuković
AuthorKsenija Maštrović Radončić
AuthorMarina Ikić Matijašević
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Background: Rheumatoid arthritis (RA) is a chronic systemic autoimmune and inflammatory disease. Conventional synthetic and biologic disease-modifying antirheumatic drugs (DMARDs), Janus kinase inhibitors, and rituximab are used to treat the disease. There are no recommendations or guidelines for the treatment of patients with both inflammatory arthritis and end-stage renal disease (ESRD), despite the safety and efficacy of the mentioned drugs. The anti-interleukin-6 receptor antibody tocilizumab (TCZ) has not been used as a long-term therapy for hemodialysis (HD) patients with RA, except in a few case reports. Case Description: We present the case of a 41-year-old patient with RA and ESRD on maintenance HD due to type 1 diabetes-related complications. Due to high RA disease activity, the patient was not a suitable candidate for a kidney transplant. Because TCZ is used to treat both RA and kidney transplant rejection, therapy with a full dose of TCZ was administered. The patient has achieved sustained clinical remission (for the past four years) with no adverse events reported. Conclusions: Herein, we present the safe and effective use of TCZ in an RA patient on HD who is also a candidate for kidney transplant. Consequently, TCZ could be the treatment of choice for RA patients with ESRD who have not achieved disease control (low activity or remission) with conventional synthetic DMARDs. Clinical studies are required to evaluate the efficacy and safety of biologic DMARDs and Janus kinase inhibitors in patients with both inflammatory arthritis and ESRD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleMedicina
Numberingvol. 59, no. 9, 1517
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina59091517
URN:NBNurn:nbn:hr:105:091889
Publication2023-08-23
Document URLhttps://www.mdpi.com/1648-9144/59/9/1517
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-05-21 07:56:36